Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Jul 28, 2011 1:16pm

209 Views

Post# 18883767

RE: Q2 results

"it's time to hire an investor relations firm. Just because all you doctors are really smart guys doesn't mean you know how run a public company. "

I couldn't agree with you more. Now that we're approaching the end game I think their (the management) inexperience is beginning to become apparent. It's one thing to know the science; it's another to sell the science. We badly need, at this juncture, a partner.

Bullboard Posts

Rising miner increases graphite price, restarts Québec mill